Exelixis, Inc. (NASDAQ:EXEL)
CAPS Rating:
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Recs
Because I was an early investor in DNDN and didn't sell in time I became curious about Exelixis, a firm competitor. I am buying in at a price below it's 52 week high. It has a lot of events coming up and I think the data revealed will move the price.